RUXOLITINIB PHOSPHATE - Generic Drug Details

What are the generic sources for ruxolitinib phosphate and what is the scope of freedom to operate?

Ruxolitinib phosphate is the generic ingredient in two branded drugs marketed by Incyte Corp and is included in two NDAs. There are twenty-two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ruxolitinib phosphate has three hundred and thirty-seven patent family members in forty-nine countries.

There are two drug master file entries for ruxolitinib phosphate. One supplier is listed for this compound.

Summary for RUXOLITINIB PHOSPHATE

International Patents:	337
US Patents:	22
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	29
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RUXOLITINIB PHOSPHATE
DailyMed Link:	RUXOLITINIB PHOSPHATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RUXOLITINIB PHOSPHATE

Dosage:

TABLET;ORAL

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RUXOLITINIB PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE1
City of Hope Medical Center	PHASE1
Jonathan Brammer	PHASE2

See all RUXOLITINIB PHOSPHATE clinical trials

Pharmacology for RUXOLITINIB PHOSPHATE

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for RUXOLITINIB PHOSPHATE

D11AH	Agents for dermatitis, excluding corticosteroids
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

L01EJ	Janus-associated kinase (JAK) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for RUXOLITINIB PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPZELURA	Cream	ruxolitinib phosphate	1.5%	215309	1	2023-07-31
JAKAFI	Tablets	ruxolitinib phosphate	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg	202192	1	2015-12-17

US Patents and Regulatory Information for RUXOLITINIB PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No					Y

International Patents for RUXOLITINIB PHOSPHATE

Country	Patent Number	Title	Estimated Expiration
Croatia	P20150837
Eurasian Patent Organization	201691294	ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
Hong Kong	1160137

Supplementary Protection Certificates for RUXOLITINIB PHOSPHATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	2013C/014	Belgium		PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828
1966202	122013000015	Germany		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	2013/004	Ireland		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823

Ruxolitinib Phosphate: Market Dynamics and Financial Trajectory

Last updated: March 5, 2026

What is Driving Market Adoption?

Ruxolitinib phosphate, marketed as Jakafi in the United States, is a Janus kinase (JAK) inhibitor approved primarily for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease. Its market growth stems from increasing prevalence of hematologic disorders, expanding approved indications, and its role in managing cytokine-driven conditions.

The global demand for JAK inhibitors is estimated to grow at a compound annual growth rate (CAGR) of approximately 11% from 2022 to 2027, driven by broader therapeutic applications and long-term unmet needs in hematology and oncology.

Market Size and Key Players

Current Market Valuation

• 2022 global Ruxolitinib market valuation: approximately USD 1.2 billion.
• Forecast by 2027: USD 2.2 billion, driven by pipeline expansion and new indications.

Leading Companies

• Incyte Corporation: Holds US rights; launched Jakafi (ruxolitinib).
• Novartis: Holds rights outside the US, actively developing derivatives and combination therapies.
• Gilead Sciences: Acquired rights via its purchase of Forty Seven Inc., expanding Ruxolitinib’s pipeline.

Patent and Commercial Landscape

• Patents protecting Ruxolitinib expire in the US by 2029, opening generics entry.
• Market exclusivity has been extended via orphan drug designations.

Market Dynamics

Regulatory Approvals and Expanding Indications

Ruxolitinib received FDA approval in 2011 for myelofibrosis. Subsequent approvals include:

• 2019 for polycythemia vera.
• 2022 for steroid-refractory chronic graft-versus-host disease.

Pipeline expansion features trials for atopic dermatitis, alopecia areata, and inflammatory conditions. This diversification mitigates revenue risks associated with dependence on hematologic indications.

Pricing and Reimbursement

• Average wholesale price (AWP) in the US: USD 81,000 per year per patient.
• Reimbursement largely supported by Medicare, Medicaid, and private insurers.
• Cost-effectiveness measures influence pricing strategies in other regions, notably Europe and Asia.

Competitive Landscape

Primary competitors include:

• Fedratinib (Sanofi): Approved for myelofibrosis, with distinct JAK2 selectivity.
• Ritlecitinib (Allakos): Under development for alopecia areata.
• Emerging JAK inhibitors target specific cytokines, influencing market share distribution.

Challenges and Risks

• Patent expiry threatens exclusivity.
• Side effect profile, including anemia and thrombocytopenia, limits use in vulnerable populations.
• Competition from newer, more selective JAK inhibitors may erode market dominance.

Financial Trajectory

Revenue Trends

• 2022 revenue: USD 1.2 billion.
• Estimated CAGR over five years: 11% (2022-2027).
• Revenue growth driven by expanding indications and international markets.

Cost and Investment Outlook

• R&D expenditures: approximately USD 350 million annually.
• Pipeline investments focus on expanding therapeutic areas and improving selectivity.
• Marketing spends increase as new indications seek approval.

Future Revenue Drivers

• Launch of combination therapies.
• Entry into dermatology and autoimmune markets.
• Strategic licensing and collaborations in emerging markets.

Market Entry and Expansion Strategies

• Patent litigation and data exclusivity will influence generic market penetration.
• Market expansion depends on regulatory approvals outside the US and Europe.
• Collaborations with local pharmaceutical firms facilitate entry into Asian and Latin American markets.

Summary of Key Data Points

Aspect	Details
2022 Market Size	USD 1.2 billion
Estimated 2027 Market Size	USD 2.2 billion
CAGR (2022-2027)	11%
Leading Company	Incyte Corporation
Main Indicated Conditions	Myelofibrosis, polycythemia vera, GvHD
Patent Expiry	2029 (US)
Wholesale Price	USD 81,000/year (US)

---

Key Takeaways

• Ruxolitinib phosphate's market growth hinges on expanding approved indications and ongoing pipeline development.
• Revenue is rising at a double-digit CAGR, supported by international expansion and pipeline diversification.
• Patent expiration in 2029 risks generic competition, but market exclusivity extensions and formulations can delay entry.
• Competition from more selective JAK inhibitors and side effect concerns frame the competitive landscape.
• Cost management and strategic partnerships are pivotal for sustaining financial performance.

FAQs

1. When is Ruxolitinib patent expiry?
Patent protections in the US are set to expire in 2029, opening the market for generics.

2. What are the primary indications for Ruxolitinib?
Myelofibrosis, polycythemia vera, and graft-versus-host disease are the main approved uses.

3. How does the pipeline influence future revenues?
Pipeline expansion into dermatology and autoimmune diseases could substantially increase revenue streams before patent expiry.

4. What factors could limit Ruxolitinib’s market growth?
Side effects and the entry of more selective JAK inhibitors could diminish market share.

5. How are pricing strategies adapted across regions?
Pricing varies with healthcare systems; higher in the US, with price negotiations and reimbursement impacting profitability elsewhere.

---

References

[1] MarketResearch.com. (2023). Global Ruxolitinib market report.
[2] Incyte Corporation. (2022). Jakafi (Ruxolitinib) prescribing information.
[3] FDA. (2022). Approval history and indications for Ruxolitinib.
[4] EvaluatePharma. (2022). Oncology and Hematology drug market projections.
[5] European Medicines Agency. (2022). Ruxolitinib approval status and patent info.